Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FOLH1 | Q04609 | 2/20 | 0.66 |
| ▸ | ALDH1A1 | P00352 | 6/20 | 0.52 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.52 |
| ▸ | TSHR | P16473 | 1/20 | 0.50 |
| ▸ | HMGB1 | P09429 | 2/20 | 0.46 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.45 |
| ▸ | CA12 | O43570 | 1/20 | 0.45 |
| ▸ | CA1 | P00915 | 1/20 | 0.45 |
| ▸ | CA2 | P00918 | 1/20 | 0.45 |
| ▸ | HPGD | P15428 | 1/20 | 0.45 |
| ▸ | CA4 | P22748 | 1/20 | 0.45 |
| ▸ | CA6 | P23280 | 1/20 | 0.45 |
| ▸ | CA7 | P43166 | 1/20 | 0.45 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.45 |
| ▸ | CA9 | Q16790 | 1/20 | 0.45 |
| ▸ | NAPRT | Q6XQN6 | 1/20 | 0.45 |
| ▸ | CA14 | Q9ULX7 | 1/20 | 0.45 |
| ▸ | TP53 | P04637 | 1/20 | 0.45 |
| ▸ | HTT | P42858 | 1/20 | 0.45 |
| ▸ | SLC16A3 | O15427 | 2/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Hydrochloric Acid SCHEMBL10627695 | 0.98 | FOLH1 (0.63) | FOLH1ALDH1A1ALOX15TSHRHMGB1 | |
| Furan SCHEMBL28136164 | 0.89 | FOLH1 (0.54) | FOLH1ALDH1A1ALOX15TSHRHMGB1 | |
| SCHEMBL8791639 | 0.88 | FOLH1 (0.61) | FOLH1ALDH1A1ALOX15TSHRHMGB1 | |
| SCHEMBL30365583 | 0.87 | FOLH1 (0.76) | FOLH1ALDH1A1ALOX15TSHRHMGB1 | |
| SCHEMBL70392 | 0.87 | FOLH1 (0.76) | FOLH1ALDH1A1ALOX15TSHRHMGB1 | |
| SCHEMBL9615025 | 0.87 | LMNA (0.60) | FOLH1ALDH1A1ALOX15TSHRKDM4E | |
| SCHEMBL27773761 | 0.85 | FOLH1 (0.47) | FOLH1ALDH1A1ALOX15TSHRHMGB1 | |
| SCHEMBL9559954 | 0.85 | FOLH1 (0.58) | FOLH1ALDH1A1ALOX15TSHRSLC16A3 | |
| SCHEMBL27393130 | 0.84 | FOLH1 (0.47) | FOLH1ALDH1A1ALOX15HTTPTPN1 | |
| SCHEMBL27625514 | 0.83 | FOLH1 (0.46) | FOLH1ALDH1A1TSHRKDM4EHPGD |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 60 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-110526856-A | The synthetic method of DWP205190 | TIANJIN RUILING CHEMICAL CO LTD | 2019-12-03 | — | — | CN | claimed |
| US-12370263-B2 | Cyclic dinucleotide derivative based antibody-drug conjugates | DAIICHI SANKYO COMPANY, LIMITED (JP) | 2025-07-29 | — | — | US | disclosed |
| EP-4524154-A2 | ANTIBODY-DRUG CONJUGATES OF CYCLIC DINUCLEOTIDE DERIVATIVES | Daiichi Sankyo Company, Limited (JP) | 2025-03-19 | — | — | EP | disclosed |
| EP-3848054-B1 | ANTIBODY-DRUG CONJUGATES OF CYCLIC DINUCLEOTIDE DERIVATIVES | DAIICHI SANKYO CO LTD (JP) | 2025-01-29 | — | — | EP | disclosed |
| CN-119291192-A | Kit for detecting content of fentanyl and analogues thereof and application of kit | 中国药科大学 | 2025-01-10 | — | — | CN | disclosed |
| US-20240293567-A1 | NOVEL CYCLIC DINUCLEOTIDE DERIVATIVE AND ANTIBODY-DRUG CONJUGATE THEREOF | DAIICHI SANKYO COMPANY, LIMITED (JP) | 2024-09-05 | — | — | US | disclosed |
| US-20230330248-A1 | ANTIBODY-DRUG CONJUGATE INCLUDING NOVEL CYCLIC DINUCLEOTIDE DERIVATIVE | DAIICHI SANKYO COMPANY, LIMITED (JP) | 2023-10-19 | — | — | US | disclosed |
| CN-113372327-B | Glutarimide skeleton-based compound and application thereof | 上海科技大学 | 2023-07-18 | — | — | CN | disclosed |
| CN-111606883-B | Sulfur-containing compound based on glutarimide skeleton and application thereof | 上海科技大学 | 2023-05-09 | — | — | CN | disclosed |
| EP-4115909-A1 | ANTIBODY-DRUG CONJUGATE INCLUDING NOVEL CYCLIC DINUCLEOTIDE DERIVATIVE | Daiichi Sankyo Company, Limited (JP) | 2023-01-11 | — | — | EP | disclosed |
| EP-1015028-A2 | METHODS TO IMPROVE IMMUNOGENICITY OF ANTIGENS AND SPECIFICITY OF ANTIBODIES | SEREX, INC. (US) | 2000-07-05 | — | — | EP | disclosed |
| EP-0975624-A1 | THERMOGENIC COMPOSITION AND BENZAZEPINE THERMOGENICS | Takeda Chemical Industries, Ltd. (JP) | 2000-02-02 | — | — | EP | disclosed |
| CN-1046711-C | Unsaturated hydroxyalkyl quinoline carboxylic acids as leukotriene antagonists | MERCK FROSST CANADA INC (CA) | 1999-11-24 | — | — | CN | disclosed |
| WO-1999013907-A9 | METHODS TO IMPROVE IMMUNOGENICITY OF ANTIGENS AND SPECIFICITY OF ANTIBODIES | SEREX INC (US) | 1999-09-10 | — | — | WO | disclosed |
| WO-1999013907-A2 | METHODS TO IMPROVE IMMUNOGENICITY OF ANTIGENS AND SPECIFICITY OF ANTIBODIES | SEREX, INC. (US) | 1999-03-25 | — | — | WO | disclosed |
| WO-1998046590-A1 | THERMOGENIC COMPOSITION AND BENZAZEPINE THERMOGENICS | TAKEDA CHEMICAL INDUSTRIES, LTD. (JP) | 1998-10-22 | — | — | WO | disclosed |
| US-5387582-A | Immunomodulators; useful in treatment and prophylaxis of diabetes, hypertension, rheumatoid arthritis and asthma | LEO PHARMACEUTICAL PRODUCTS LTD. A/S (LOVENS KEMISKE FABRIK PRODUKTIONSAKTIESEL SKAB) (DK) | 1995-02-07 | — | — | US | disclosed |
| US-5374615-A | Treating hypertension and congestive heart failure, preventing cardiac hypertrophy | E. R. SQUIBB & SONS, INC. (US) | 1994-12-20 | — | — | US | disclosed |
| EP-0506794-B1 | NOVEL VITAMIN D ANALOGUES | LEO PHARM PROD LTD (DK) | 1994-08-24 | — | — | EP | disclosed |
| EP-0488532-A1 | Indole- and benzimidazole-substituted imidazole and benzimidazole derivatives | E.R. Squibb & Sons, Inc. (US) | 1992-06-03 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12370263-B2 | Cyclic dinucleotide derivative based antibody-drug conjugates | STING1, CGAS, CDA | FOLH1 1416/4885ALDH1A1 4189/4885ALOX15 2120/4885 |
| US-20230330248-A1 | ANTIBODY-DRUG CONJUGATE INCLUDING NOVEL CYCLIC DINUCLEOTIDE DERIVATIVE | STING1, CGAS, TLR9 | FOLH1 291/4885ALDH1A1 3436/4885ALOX15 1775/4885 |
| US-20240293567-A1 | NOVEL CYCLIC DINUCLEOTIDE DERIVATIVE AND ANTIBODY-DRUG CONJUGATE THEREOF | STING1, CGAS, TLR9 | FOLH1 1267/4885ALDH1A1 4336/4885ALOX15 2182/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.